US FDA concerned over negotiations schedule for next medtech user fee programme
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has expressed concern over the protracted negotiations it is having with the medtech industry over reauthorising its medical device user fee programme, minutes from a 2 August meeting between the FDA and industry have revealed1.